The Effectiveness of Vonoprazan Fumarate for Laryngopharyngeal Reflux Disease
Study Overview
This study investigates how well vonoprazan fumarate treats laryngopharyngeal reflux disease (LPRD) using the Chinese version of the RSS-12 scale. A total of 100 patients were involved, split into two groups of 50.
Treatment Groups
- Observation Group: Received vonoprazan fumarate (20 mg, once daily).
- Control Group: Received esomeprazole (20 mg, twice daily).
Results Summary
Before treatment, there were no significant differences in symptoms between the two groups. After 8 and 12 weeks of treatment:
- Both groups showed a significant decrease in RSS-12 and RSI scores.
- The most noticeable symptom improvement occurred between weeks 0-8.
- At 12 weeks, 80% of the observation group had a good response compared to 64% in the control group.
- For RSI scores, 90% of the observation group responded well, compared to 84% in the control group.
Overall, the treatment effects were similar between the two groups.
Conclusion
Vonoprazan fumarate effectively improves symptoms of LPRD and works as well as traditional proton pump inhibitors. The Chinese version of RSS-12 can be a useful new tool for diagnosing LPRD in clinical settings.
Enhancing Clinical Trials and Patient Care
Clinical trials are essential for developing safe and effective treatments. To ensure these benefits reach everyday medical practice, we offer DocSym, an AI-driven platform that consolidates ICD-11 standards, clinical protocols, and research into one easy-to-use knowledge base for healthcare providers.
Streamlined Operations
In today’s healthcare environment, efficiency is key. Our mobile apps help with:
- Scheduling appointments
- Monitoring treatments
- Facilitating telemedicine
This makes managing patient care easier and expands digital service offerings.
Improving Outcomes with AI
By leveraging AI, clinics can enhance workflows, improve patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
